Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Focal/grid since 1985, laser photocoagulation has been the mainstay of treatment for clinically significant (diabetic) macular edema, according to the Early Treatment Diabetic Retinopathy Study (ETDRS). Leaky microaneurysms are treated with a concentrated laser, whereas diffuse leaking is treated using a grid pattern of larger burns of light intensity at the retinal pigment epithelium level. to compare ranibizumab versus biosimilar in terms of how it affects macular thickness and vision in patients with clinically significant diabetic macular oedema (DME). The current investigation was prospective and observational. This study was carried out in the Department of Ophthalmology at Vivekananda Institute of Medical Sciences, RKMSP, Kolkata, from January 2018 to June 2019. Pretreatment ‐ day 00 visual acuity distribution compared to group did not show statistical significance (p = 0.3990).There was a statistically significant difference in the mean visual acuity between the groups on treatment days 90 (p = 0.0167) and 180 (p = 0.0034). D1 fundus distribution versus Group study‐ In group A (Ranibizumab), 100% of patients developed Diabetic macular edema (DME), while 100% of patients in group B (Biosimilar Ranibizumab) also had DME. The relationship between D30 Fundus and Group (p = 0.32718), D90 Fundus and Group (p = 0.7402695825) and D180 Fundus and Group (p = 0.7402695825) was not statistically significant. We conclude that after measuring the central macular thickness, we found that Group A experienced a larger decline in CMT on D30 and D180 than did Group B.
How to cite this article:
Suchandra Das and Bijan Mallick. Comparative Analysis of Ranibizumab Versus Biosimilar Ranibizumab in Clinically Significan Diabetic M Acular Oedema.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.5.364.369
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.5.364.369